

Wolfgang Greiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2180424/publications.pdf>

Version: 2024-02-01

108
papers

4,595
citations

186209

28
h-index

114418

63
g-index

140
all docs

140
docs citations

140
times ranked

6156
citing authors

#	ARTICLE	IF	CITATIONS
1	Developing and testing a cognitive bolt-on for the EQ-5D-Y (Youth). <i>Quality of Life Research</i> , 2022, 31, 215-229.	1.5	2
2	Childhood Allergy and tolerance: Biomarkers and Predictors (CHAMP) and quality of life. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	1.1	2
3	Feasibility of the EQ-5D in the elderly population: a systematic review of the literature. <i>Quality of Life Research</i> , 2022, 31, 1621-1637.	1.5	18
4	An Innovative Telemedical Network to Improve Infectious Disease Management in Critically Ill Patients and Outpatients (TELnet@NRW): Stepped-Wedge Cluster Randomized Controlled Trial. <i>Journal of Medical Internet Research</i> , 2022, 24, e34098.	2.1	16
5	Public Health Impact and Cost-Effectiveness Analysis of Routine Infant 4CMenB Vaccination in Germany to Prevent Serogroup AB Invasive Meningococcal Disease. <i>Infectious Diseases and Therapy</i> , 2022, 11, 367-387.	1.8	4
6	Developing a New Generic Health and Wellbeing Measure: Psychometric Survey Results for the EQ-HWB. <i>Value in Health</i> , 2022, 25, 525-533.	0.1	25
7	Use of an electronic medication management support system in patients with polypharmacy in general practice: study protocol of a quantitative process evaluation of the AdAM trial. <i>Therapeutic Advances in Drug Safety</i> , 2022, 13, 204209862110732.	1.0	2
8	Epidemiology and economic burden of meningococcal disease in Germany: A systematic review. <i>Vaccine</i> , 2022, 40, 1932-1947.	1.7	4
9	The EQ-HWB: Overview of the Development of a Measure of Health and Wellbeing and Key Results. <i>Value in Health</i> , 2022, 25, 482-491.	0.1	45
10	Generation, Selection, and Face Validation of Items for a New Generic Measure of Quality of Life: The EQ-HWB. <i>Value in Health</i> , 2022, 25, 512-524.	0.1	12
11	Burden of CIN2+ diagnoses and conizations in women aged 18-45 years: a retrospective secondary data analysis of German statutory health insurance claims data. <i>Archives of Gynecology and Obstetrics</i> , 2022, 306, 2077-2092.	0.8	1
12	Effectiveness of a multi-component community-based care approach for older people at risk of care dependency - results of a prospective quasi-experimental study. <i>BMC Geriatrics</i> , 2022, 22, 348.	1.1	3
13	Letter to the editor by Rosslénbroich, Greiner, Gensorowsky, Grosser, Hasebrook, Schaumburg, Raschke with regard to: Establishment of an interdisciplinary board for bone and joint by Otto-Lambertz et al. https://doi.org/10.1007/s15010-021-01676-9 . <i>Infection</i> , 2022, , 1.	2.3	0
14	Feasibility properties of the EQ-5D-3L and 5L in the general population: evidence from the GP Patient Survey on the impact of age. <i>Health Economics Review</i> , 2022, 12, 28.	0.8	2
15	EQ-5D-Y Value Set for Germany. <i>Pharmacoeconomics</i> , 2022, 40, 217-229.	1.7	17
16	Healthcare Costs and Resource Use Associated With Cervical Intraepithelial Neoplasia and Cervical Conization: A Retrospective Study of German Statutory Health Insurance Claims Data. <i>Journal of Health Economics and Outcomes Research</i> , 2022, 9, 128-139.	0.6	1
17	Market access and value-based pricing of digital health applications in Germany. <i>Cost Effectiveness and Resource Allocation</i> , 2022, 20, .	0.6	8
18	The Influence of Remote monitoring on Anxiety/depResion, quality of life, and Device acceptance in ICD patients: a prospective, randomized, controlled, single-center trial. <i>Clinical Research in Cardiology</i> , 2021, 110, 789-800.	1.5	9

#	ARTICLE	IF	CITATIONS
19	High-Expenditure Disease in the EU-28: Does Drug Spend Correspond to Clinical and Economic Burden in Oncology, Autoimmune Disease and Diabetes?. <i>PharmacoEconomics - Open</i> , 2021, 5, 385-396.	0.9	11
20	EQ-5D-5L reference values for the German general elderly population. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 76.	1.0	36
21	Burden of Herpes Zoster in Adult Patients with Underlying Conditions: Analysis of German Claims Data, 2007-2018. <i>Dermatology and Therapy</i> , 2021, 11, 1009-1026.	1.4	18
22	Health economic burden of patients with phenylketonuria (PKU) - A retrospective study of German health insurance claims data. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 27, 100764.	0.4	4
23	Comparison of Adult and Adolescent Preferences Toward EQ-5D-Y-3L Health States. <i>Value in Health</i> , 2021, 24, 1350-1359.	0.1	9
24	To What Extent Do Patient Preferences Differ From General Population Preferences?. <i>Value in Health</i> , 2021, 24, 1343-1349.	0.1	11
25	Effectiveness of the application of an electronic medication management support system in patients with polypharmacy in general practice: a study protocol of cluster-randomised controlled trial (AdAM). <i>BMJ Open</i> , 2021, 11, e048191.	0.8	8
26	Cost-Effectiveness of Routine Childhood Vaccination Against Seasonal Influenza in Germany. <i>Value in Health</i> , 2021, 24, 32-40.	0.1	10
27	Optimization of sepsis therapy based on patient-specific digital precision diagnostics using next generation sequencing (DigiSep-Trial)-study protocol for a randomized, controlled, interventional, open-label, multicenter trial. <i>Trials</i> , 2021, 22, 714.	0.7	10
28	Patient-Reported Financial Distress in Cancer: A Systematic Review of Risk Factors in Universal Healthcare Systems. <i>Cancers</i> , 2021, 13, 5015.	1.7	18
29	Telemedizin - Bewertung des Nutzens. , 2021, , 483-496.		2
30	Considering the societal perspective in economic evaluations: a systematic review in the case of depression. <i>Health Economics Review</i> , 2020, 10, 32.	0.8	18
31	HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. <i>European Journal of Health Economics</i> , 2020, 21, 1421-1437.	1.4	38
32	Application study of the EQ-5D-5L in oncology: linking self-reported quality of life of patients with advanced or metastatic colorectal cancer to clinical data from a German tumor registry. <i>Health Economics Review</i> , 2020, 10, 40.	0.8	14
33	Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines. <i>European Journal of Health Economics</i> , 2020, 21, 1245-1257.	1.4	148
34	Reduction of potentially inappropriate medication in the elderly: design of a cluster-randomised controlled trial in German primary care practices (RIME). <i>Therapeutic Advances in Drug Safety</i> , 2020, 11, 204209862091845.	1.0	6
35	Health economic evaluation of an internet intervention for depression (deprexis), a randomized controlled trial. <i>Health Economics Review</i> , 2020, 10, 19.	0.8	16
36	The patient-level effect of the cost of Cancer care - financial burden in German Cancer patients. <i>BMC Cancer</i> , 2020, 20, 529.	1.1	30

#	ARTICLE	IF	CITATIONS
37	Health Preference Research in Europe: A Review of Its Use in Marketing Authorization, Reimbursement, and Pricing Decisions Report of the ISPOR Stated Preference Research Special Interest Group. <i>Value in Health</i> , 2020, 23, 831-841.	0.1	37
38	Epidemiology and cost of seasonal influenza in Germany - a claims data analysis. <i>BMC Public Health</i> , 2019, 19, 1090.	1.2	25
39	Retrospective analysis into differences in heart failure patients with and without iron deficiency or anaemia. <i>ESC Heart Failure</i> , 2019, 6, 840-855.	1.4	18
40	The cost-of-illness for invasive meningococcal disease caused by serogroup B <i>Neisseria meningitidis</i> (MenB) in Germany. <i>Vaccine</i> , 2019, 37, 1692-1701.	1.7	22
41	EQ-5D-Y as a Health-Related Quality of Life Instrument for Children and Adolescents: The Instrument's Characteristics, Development, Current Use, and Challenges of Developing Its Value Set. <i>Value in Health</i> , 2019, 22, 31-37.	0.1	85
42	A DELPHI study on aspects of study design to overcome knowledge gaps on the burden of disease caused by serogroup B invasive meningococcal disease. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 87.	1.0	6
43	Health economic evaluation of a web-based intervention for depression: the EVIDENT-trial, a randomized controlled study. <i>Health Economics Review</i> , 2019, 9, 16.	0.8	13
44	Population size and self-reported characteristics and sexual preferences of men-who-have-sex-with-men (MSM) in Germany based on social network data. <i>PLoS ONE</i> , 2019, 14, e0212175.	1.1	4
45	EQ-5D-Y-5L: developing a revised EQ-5D-Y with increased response categories. <i>Quality of Life Research</i> , 2019, 28, 1951-1961.	1.5	47
46	Der Kinder- und Jugendreport der DAK-Gesundheit: Eine neue Datengrundlage für die pädiatrische Gesundheitsforschung. <i>Public Health Forum</i> , 2019, 27, 324-326.	0.1	2
47	PP177 Health Preference Research In Europe: A Review Of Its Use. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 70-70.	0.2	0
48	An exclusive human milk diet for very low birth weight newborns A cost-effectiveness and EVPI study for Germany. <i>PLoS ONE</i> , 2019, 14, e0226496.	1.1	6
49	Title is missing!. , 2019, 14, e0226496.		0
50	Title is missing!. , 2019, 14, e0226496.		0
51	Title is missing!. , 2019, 14, e0226496.		0
52	Title is missing!. , 2019, 14, e0226496.		0
53	Influence of demographic changes on the impact of vaccination against varicella and herpes zoster in Germany a mathematical modelling study. <i>BMC Medicine</i> , 2018, 16, 3.	2.3	18
54	German Value Set for the EQ-5D-5L. <i>Pharmacoeconomics</i> , 2018, 36, 663-674.	1.7	316

#	ARTICLE	IF	CITATIONS
55	Welchen Beitrag kann die Gesundheitsökonomie im Kontext von Public Health leisten?. Public Health Forum, 2018, 26, 283-285.	0.1	3
56	Valuation of EuroQol Five-Dimensional Questionnaire, Youth Version (EQ-5D-Y) and EuroQol Five-Dimensional Questionnaire, Three-Level Version (EQ-5D-3L) Health States: The Impact of Wording and Perspective. Value in Health, 2018, 21, 1291-1298.	0.1	70
57	Bridging the "digital divide": A comparison of use and effectiveness of an online intervention for depression between Baby Boomers and Millennials. Journal of Affective Disorders, 2018, 236, 243-251.	2.0	25
58	Valuation of the EQ-5D-5L with composite time trade-off for the German population " an exploratory study. Health and Quality of Life Outcomes, 2017, 15, 39.	1.0	16
59	Time to remission from mild to moderate depressive symptoms: One year results from the EVIDENT-study, an RCT of an internet intervention for depression. Behaviour Research and Therapy, 2017, 97, 154-162.	1.6	24
60	Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation, 2017, 15, 18.	0.6	24
61	Die Arzneimittelnutzenbewertung " Rückblick und Ausblick. Public Health Forum, 2017, 25, 235-237.	0.1	1
62	Defining and Predicting Patterns of Early Response in a Web-Based Intervention for Depression. Journal of Medical Internet Research, 2017, 19, e206.	2.1	31
63	Barriers and Strategies in Guideline Implementation" A Scoping Review. Healthcare (Switzerland), 2016, 4, 36.	1.0	509
64	Valuation of Child Health-Related Quality of Life in the United States. Health Economics (United Kingdom) 32, 10, 1071-1087.	0.8	32
65	Epidemiology and economic burden of measles, mumps, pertussis, and varicella in Germany: a systematic review. International Journal of Public Health, 2016, 61, 847-860.	1.0	29
66	Effects of a Psychological Internet Intervention in the Treatment of Mild to Moderate Depressive Symptoms: Results of the EVIDENT Study, a Randomized Controlled Trial. Psychotherapy and Psychosomatics, 2016, 85, 218-228.	4.0	124
67	Current and future effects of varicella and herpes zoster vaccination in Germany " Insights from a mathematical model in a country with universal varicella vaccination. Human Vaccines and Immunotherapeutics, 2016, 12, 1-11.	1.4	21
68	Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics Community. Pharmacoeconomics, 2016, 34, 227-244.	1.7	97
69	Healthcare costs and resource utilization of asthma in Germany: a claims data analysis. European Journal of Health Economics, 2016, 17, 195-201.	1.4	30
70	Regional differences of outpatient physician supply as a theoretical economic and empirical generalized linear model. Human Resources for Health, 2015, 13, 85.	1.1	13
71	Kollektiv-ergänzende Kapitaldeckung in der sozialen Pflegeversicherung " Wirkungen des Pflegevorsorgefonds auf die Beitragssatzentwicklung. Zeitschrift Fur Sozialreform, 2015, 61, 199-224.	0.7	3
72	Which Metrics Are Appropriate to Describe the Value of New Cancer Therapies?. BioMed Research International, 2015, 2015, 1-9.	0.9	19

#	ARTICLE	IF	CITATIONS
73	Effects of an Internet intervention (Deprexis) on severe depression symptoms: Randomized controlled trial. <i>Internet Interventions</i> , 2015, 2, 48-59.	1.4	149
74	Can adult weights be used to value child health states? Testing the influence of perspective in valuing EQ-5D-Y. <i>Quality of Life Research</i> , 2015, 24, 2519-2539.	1.5	54
75	Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries. <i>BMC Public Health</i> , 2015, 15, 533.	1.2	40
76	Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. <i>European Journal of Health Economics</i> , 2015, 16, 471-488.	1.4	32
77	Kosten sozialrechtlich anerkannter Pflegebedürftigkeit im Querschnitt. <i>Zeitschrift Fur Sozialreform</i> , 2014, 60, 349-378.	0.7	1
78	Entwicklung der Leistungsempfängerzahlen in der Gesetzlichen Pflegeversicherung – Zum Einfluss unterschiedlicher Morbiditätsannahmen auf die Entwicklung der sozialrechtlich anerkannten Pflegebedürftigkeit in Deutschland. <i>Schmollers Jahrbuch</i> , 2014, 134, 209-236.	0.2	1
79	Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 509-521.	1.0	30
80	Treatment costs of attention deficit hyperactivity disorder in Germany. <i>European Journal of Health Economics</i> , 2013, 14, 939-945.	1.4	22
81	The EVIDENT-trial: protocol and rationale of a multicenter randomized controlled trial testing the effectiveness of an online-based psychological intervention. <i>BMC Psychiatry</i> , 2013, 13, 239.	1.1	47
82	Bevölkerungsentwicklung und soziale Pflegeversicherung in Deutschland. Der Einfluss von demografischen Faktoren auf das Verhältnis von potenziellen Beitragszahlern und Leistungsbeziehern. <i>Zeitschrift Fur Sozialreform</i> , 2013, 59, 433-458.	0.7	3
83	4 Der EQ-5D der EuroQol-Gruppe. , 2012, , 411-422.		9
84	Wirtschaftliche Potentiale individualisierter Medizin. <i>PharmacoEconomics - German Research Articles</i> , 2011, 9, 45-54.	0.1	5
85	HTA in Germany: very special and specific. <i>European Journal of Health Economics</i> , 2010, 11, 1-3.	1.4	3
86	Development of the EQ-5D-Y: a child-friendly version of the EQ-5D. <i>Quality of Life Research</i> , 2010, 19, 875-886.	1.5	574
87	Feasibility, reliability, and validity of the EQ-5D-Y: results from a multinational study. <i>Quality of Life Research</i> , 2010, 19, 887-897.	1.5	325
88	Cost Effectiveness of Exemestane versus Tamoxifen in Post-Menopausal Women with Early Breast Cancer in Germany. <i>Breast Care</i> , 2009, 4, 389-396.	0.8	6
89	Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europe – The HEALTH Model. <i>Value in Health</i> , 2009, 12, 857-871.	0.1	15
90	Methods of Economic Evaluation for the German Statutory Healthcare System. <i>Pharmacoeconomics</i> , 2009, 27, 265.	1.7	0

#	ARTICLE	IF	CITATIONS
91	Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors. <i>GMS Health Technology Assessment</i> , 2009, 5, Doc04.	2.2	2
92	Efficacy and cost-effectiveness of the 13C-urea breath test as the primary diagnostic investigation for the detection of <i>Helicobacter pylori</i> infection compared to invasive and non-invasive diagnostic tests. <i>GMS Health Technology Assessment</i> , 2009, 5, Doc14.	2.2	17
93	Behavioural and skill-based early interventions in children with autism spectrum disorders. <i>GMS Health Technology Assessment</i> , 2009, 5, Doc10.	2.2	2
94	Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease. <i>GMS Health Technology Assessment</i> , 2009, 5, Doc16.	2.2	4
95	Cost-effectiveness of smoking prevention measures in adolescents. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2008, 16, 3-11.	0.8	2
96	German Recommendations on Health Economic Evaluation: Third and Updated Version of the Hanover Consensus. <i>Value in Health</i> , 2008, 11, 539-544.	0.1	138
97	Scientific Guidelines and Their Implementation in Health Policy. <i>Value in Health</i> , 2008, 11, 547-548.	0.1	3
98	Cataract Surgery and the Development or Progression of Age-related Macular Degeneration: A Systematic Review. <i>Survey of Ophthalmology</i> , 2008, 53, 359-367.	1.7	61
99	Methods for determining cost-benefit ratios for pharmaceuticals in Germany. <i>European Journal of Health Economics</i> , 2007, 8, 5-31.	1.4	44
100	Medical effectiveness and safety of conventional compared to laparoscopic incisional hernia repair: A systematic review. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2007, 21, 2127-2136.	1.3	48
101	Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. <i>European Journal of Health Economics</i> , 2006, 7, 290-296.	1.4	28
102	Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α -2b plus ribavirin as initial treatment of chronic hepatitis C in Germany. <i>European Journal of Health Economics</i> , 2005, 6, 112-123.	1.4	18
103	Health economic evaluation of disease management programs. <i>European Journal of Health Economics</i> , 2005, 6, 191-196.	1.4	13
104	Cost-effectiveness of outpatient treatment in depressive patients with escitalopram in Germany. <i>European Journal of Health Economics</i> , 2005, 6, 317-321.	1.4	18
105	A single European currency for EQ-5D health states. <i>European Journal of Health Economics</i> , 2003, 4, 222-231.	1.4	388
106	Cost of care and clinical condition in paediatric cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2003, 2, 84-90.	0.3	72
107	Empfehlungen zu gesundheitsökonomischen Methoden und Designs in Public Health. <i>Public Health Forum</i> , 2000, 8, 7-10.	0.1	0
108	A Multinational Economic Evaluation of rhDNase in the Treatment of Cystic Fibrosis. <i>International Journal of Technology Assessment in Health Care</i> , 1996, 12, 52-61.	0.2	45